Discontinued — last reported Q1 '20
Thermo Fisher Scientific Contract Liabilities increased by 3.3% to $1.16B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 18.8%, from $1.43B to $1.16B. Over 4 years (FY 2020 to FY 2024), Contract Liabilities shows an upward trend with a 10.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase is a positive sign of strong sales momentum and future revenue growth, while a decrease may suggest slowing bookings.
Payments received from customers in advance of the company delivering products or performing services, often referred to...
This is a primary metric for cloud peers like Salesforce or Amazon Web Services to track the health of their subscription pipelines.
contract_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $781.00M | $822.00M | $1.24B | $1.29B | $1.24B | $1.20B | $1.18B | $1.17B | $1.10B | $1.35B | $1.50B | $1.43B | $1.46B | $1.43B | $1.14B | $1.13B | $1.12B | $1.16B |
| QoQ Change | — | +5.2% | +50.6% | +4.5% | -4.4% | -3.0% | -1.8% | -0.6% | -6.3% | +22.8% | +11.2% | -4.8% | +2.0% | -1.9% | -20.3% | -1.0% | -0.4% | +3.3% |
| YoY Change | — | — | — | — | +58.4% | +46.0% | -4.8% | -9.4% | -11.2% | +12.3% | +27.1% | +21.8% | +32.5% | +5.9% | -24.1% | -21.0% | -22.9% | -18.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.